Nancy J. Linck
Geen lopende functies
Profiel
Nancy J.
Linck has been Senior Vice President of Intellectual Property & Regulatory Affairs and Chief Compliance Counsel for Guilford Pharmaceuticals, Inc. since February 2004.
She received a BS from the University of California at Berkeley, an MS and a PhD from the University of California in San Diego and a JD from the Western New England College School of Law.
Eerdere bekende functies van Nancy J. Linck
| Bedrijven | Functie | Einde |
|---|---|---|
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Algemeen Adviseur | 03-10-2005 |
Opleiding van Nancy J. Linck
| University of California, Berkeley | Undergraduate Degree |
| University of California San Diego | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
